Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SLX 0528

Next Previous
X
Search
Drug Profile

SLX 0528

Alternative Names: ARN-6039; BOS 172767; SLX-0528; XT 0528

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrien Pharmaceuticals
  • Developer Arrien Pharmaceuticals; Boston Pharmaceuticals; Signalexis; Xenter
  • Class Antineoplastics; Antipsoriatics; Eye disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators; Nuclear receptor subfamily 1 group F member 3 inverse agonists; Th17 cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Neuromyelitis optica; Pancreatic cancer; Psoriasis
  • No development reported Autoimmune disorders; Multiple sclerosis; Unspecified

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Jordan (PO)
  • 18 Jan 2024 Signalexis plans a phase II trial for Pancreatic cancer and Malignant Melanoma in Q2 2024 (Signalexis pipeline, January 2024)
  • 13 Dec 2023 Phase-I clinical trials in Malignant melanoma (PO), before December 2023 (Signalexis pipeline, December 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top